electroCore

214 articles about electroCore

• electroCore to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

  9/7/2023

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger, will present at the H.C. Wainwright 25th Annual Global Investment Conference.

• electroCore Announces Dismissal of All Litigation Related to Its 2018 Initial Public Offering

  8/23/2023

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic and wellness company, today announced that it has been completely vindicated in the securities class actions over the company’s 2018 initial public offering brought in the federal and state courts of New Jersey.

• electroCore Announces Second Quarter 2023 Financial Results

  8/9/2023

  electroCore, Inc., a commercial-stage bioelectronic medicine company and wellness company, announced second quarter 2023 financial results and provided an operational update.

• electroCore to Announce Second Quarter Financial Results on Wednesday, August 9

  8/1/2023

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the second quarter ended June 30, 2023, after the close of the market on Wednesday, August 9, 2023.

• electroCore, Inc. Announces $8.145 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules

  7/31/2023

  electroCore, Inc.today announced that it has agreed to issue and sell to certain institutional and accredited investors an aggregate of 1,675,914 registered shares of common stock (or common stock equivalents) and unregistered warrants to purchase up to an aggregate of 837,955 shares of common stock.

• gammaCore (Non-Invasive Vagus Nerve Stimulation; nVNS) Improves Attention and Memory in Patients with Posttraumatic Stress Disorder (PTSD)

  7/25/2023

  electroCore, Inc. today announced the publication of a peer reviewed manuscript,  Effect of Transcutaneous Cervical Vagus Nerve Stimulation on Declarative and Working Memory in Patients with Posttraumatic Stress Disorder (PTSD): A Pilot Study,  in the Journal of Affective Disorders. 

• electroCore, Inc. Announces Distribution Agreement with Reliefband Technologies, LLC

  7/13/2023

  electroCore, Inc. announced today that Reletex TM by Reliefband, the first and only FDA cleared non-invasive neuromodulation device available by prescription for nausea and vomiting, will be distributed and billed exclusively by electroCore, Inc. within the Department of Veterans Affairs (VA) and other Federal Supply Schedule (FSS) eligible entities.

• TAC-STIM™ Non-Invasive Vagal Nerve Stimulation Selected for Inclusion in the Air Force Research Laboratories Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments Project

  6/27/2023

  electroCore, Inc. (Nasdaq: ECOR) today announced that its TAC-STIM non-invasive vagus nerve stimulation (“nVNS”) Human Performance product, has been selected to be a part of the Air Force Research Laboratories (AFRL) Real-Time Assessing and Augmenting Cognitive Performance in Extreme Environments (A2PEX) Grant Program.

• electroCore to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC

  6/14/2023

  electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced that Company CEO, Dan Goldberger, will present at the Healthcare Virtual Conference Part II, presented by Maxim Group LLC and hosted by M-Vest.

• electroCore to Participate at 13th Annual LD Micro Invitational XIII

  5/23/2023

  electroCore, Inc. today announced that electroCore’s Chief Executive Officer, Dan Goldberger, will present at the 13th Annual LD Micro Invitational XIII in Los Angeles, California from June 6-8, 2023.

• electroCore Announces First Quarter 2023 Financial Results

  5/3/2023

  electroCore, Inc., a commercial-stage bioelectronic medicine company and wellness company, announced first quarter 2023 financial results and provided an operational update.

• electroCore to Participate at Annual Aegis Virtual Conference

  5/1/2023

  electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced that electroCore’s Chief Executive Officer, Dan Goldberger, will present at the Annual Aegis Virtual Conference being held May 2-4, 2023.

• National Institutes of Health Awards Grant for Pivotal Clinical Trial of gammaCore™ (nVNS) in Patients with Opioid Use Disorders

  4/26/2023

  electroCore, Inc. announced that the National Institute on Drug Abuse, part of the National Institutes of Health, has awarded Emory University and the Georgia Institute of Technology a 3-year, $6.0 million grant through the NIH Helping to End Addiction Long Term Initiative to conduct a pivotal clinical trial of gammaCore for the treatment of opioid use disorder.

• electroCore to Announce First Quarter Financial Results on Wednesday, May 3

  4/19/2023

  electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that it will report financial results for the first quarter ended March 31, 2023, after the close of the market on Wednesday, May 3, 2023.

• electroCore Provides Select First Quarter 2023 Financial Guidance

  4/17/2023

  electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today provided select preliminary unaudited financial guidance for the first quarter of 2023.

• electroCore, Inc. Announces Product Registration in Indonesia, Malaysia and South Africa

  4/6/2023

  electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced the receipt of a license to import, distribute and market gammaCore Sapphire™, non-invasive vagus nerve stimulator in Indonesia.

• electroCore, Inc. Announces gammaCore Non-Invasive Vagus Nerve Stimulator Available Through the Carrick Institute

  4/4/2023

  electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that the gammaCore Sapphire™ non-invasive vagus nerve stimulator (nVNS) will be available for purchase by clinicians through the Carrick Institute for Graduate Studies which provides clinical neuroscience education.

• electroCore Reports Results of Pre-Clinical Trial in a Model of Traumatic Brain Injury

  3/23/2023

  electroCore, Inc. today announced the publication of a paper entitled “Non-Invasive Vagus Nerve Stimulation Improves Brain Lesion Volume and Neurobehavioral Outcomes in a Rat Model of Traumatic Brain Injury” in the peer-reviewed Journal of Neurotrauma.

• electroCore Affirms No Direct Exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank

  3/14/2023

  electroCore, Inc., a commercial-stage bioelectronic medicine and wellness company, announced it does not have direct exposure to Silicon Valley Bank, Silvergate Bank, or Signature Bank.

• electroCore to Participate at 35th Annual Roth Conference

  3/9/2023

  electroCore, Inc. (the “Company”), (NASDAQ: ECOR) a commercial-stage bioelectronic medicine and wellness company, today announced that electroCore’s Chief Strategy Officer, Joshua Lev, will participate in a fireside chat at the 35th Annual Roth Conference in Dana Point, California during March 12-14, 2023.